Claims
- 1. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 44 to nucleotide 1204; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 1 to nucleotide 403; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ26—3 deposited under accession number ATCC 98115; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ26—3 deposited under accession number ATCC 98115; (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ26—3 deposited under accession number ATCC 98115; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ26—3 deposited under accession number ATCC 98115; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 2. A composition of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
- 3. A host cell transformed with a composition of claim 2.
- 4. The host cell of claim 3, wherein said cell is a mammalian cell.
- 5. A process for producing a protein encoded by a composition of claim 2, which process comprises:
(a) growing a culture of the host cell of claim 3 in a suitable culture medium; and (b) purifying said protein from the culture.
- 6. A protein produced according to the process of claim 5.
- 7. The protein of claim 6 comprising a mature protein.
- 8. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2; (b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120; (c) fragments of the amino acid sequence of SEQ ID NO:2; and (d) the amino acid sequence encoded by the cDNA insert of clone AJ26—3 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 9. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
- 10. The composition of claim 8, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 120.
- 11. The composition of claim 8, further comprising a pharmaceutically acceptable carrier.
- 12. A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 11.
- 13. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.
- 14. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 928 to nucleotide 2541; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 988 to nucleotide 2541; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 684 to nucleotide 1128; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone AJ172—2 deposited under accession number ATCC 98115; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone AJ172—2 deposited under accession number ATCC 98115; (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone AJ172—2 deposited under accession number ATCC 98115; (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone AJ172—2 deposited under accession number ATCC 98115; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4; a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above; and (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
- 15. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:4; (b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 67; (c) fragments of the amino acid sequence of SEQ ID NO:4; and (d) the amino acid sequence encoded by the cDNA insert of clone AJ172—2 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 16. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.
- 17. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:6, SEQ ID NO:5 or SEQ ID NO:8.
- 18. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 6 to nucleotide 2408; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1295 to nucleotide 1705; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL89—13 deposited under accession number ATCC 98115; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL89—13 deposited under accession number ATCC 98115; (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL89—13 deposited under accession number ATCC 98115; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL89—13 deposited under accession number ATCC 98115; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 19. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:10; (b) the amino acid sequence of SEQ ID NO:10 from amino acid 431 to amino acid 567; (c) fragments of the amino acid sequence of SEQ ID NO:10; and (d) the amino acid sequence encoded by the cDNA insert of clone BL89—13 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 20. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.
- 21. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2113 to nucleotide 2337; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 2036 to nucleotide 2316; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone BL341—4 deposited under accession number ATCC 98115; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone BL341—4 deposited under accession number ATCC 98115; (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone BL341—4 deposited under accession number ATCC 98115; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone BL341—4 deposited under accession number ATCC 98115; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 22. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:12; (b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 68; (c) fragments of the amino acid sequence of SEQ ID NO:12; and (d) the amino acid sequence encoded by the cDNA insert of clone BL341—4 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 23. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.
- 24. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 144 to nucleotide 257; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 30 to nucleotide 271; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC25—17 deposited under accession number ATCC 98115; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC25—17 deposited under accession number ATCC 98115; (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC25—17 deposited under accession number ATCC 98115; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC25—17 deposited under accession number ATCC 98115; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity; (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 25. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:16; (b) fragments of the amino acid sequence of SEQ ID NO:16; and (c) the amino acid sequence encoded by the cDNA insert of clone CC25—17 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 26. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.
- 27. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 431 to nucleotide 520; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 266 to nucleotide 511; (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone CC397—19 deposited under accession number ATCC 98115; (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone CC397—19 deposited under accession number ATCC 98115; (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone CC397—19 deposited under accession number ATCC 98115; (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone CC397—19 deposited under accession number ATCC 98115; (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18; (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity; a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and (l) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- 28. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:18; (b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 27; (c) fragments of the amino acid sequence of SEQ ID NO:18; and (d) the amino acid sequence encoded by the cDNA insert of clone CC397—19 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 29. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17.
- 30. A composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41; (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 218 to nucleotide 1159; (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 806 to nucleotide 1159; (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 217 to nucleotide 517; (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone K483—1 deposited under accession number ATCC 98115; (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone K483—1 deposited under accession number ATCC 98115; (g) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone K483—1 deposited under accession number ATCC 98115; (h) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone K483—1 deposited under accession number ATCC 98115; (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42; (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity; (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above; (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above; and (m) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j).
- 31. A composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:42; (b) the amino acid sequence of SEQ ID NO:42 from amino acid 1 to amino acid 100; (c) fragments of the amino acid sequence of SEQ ID NO:42; and (d) the amino acid sequence encoded by the cDNA insert of clone K483—1 deposited under accession number ATCC 98115; the protein being substantially free from other mammalian proteins.
- 32. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:41.
- 33. A method of promoting cell-cell fusion, said method comprising contacting a first cell and a second cell, wherein said first cell expresses an AJ172—2 protein.
- 34. The method of claim 33, wherein said first cell naturally expresses said AJ172—2 protein.
- 35. The method of claim 34, wherein said first cell expresses said AJ172—2 protein as a result of transfection of said first cell.
- 36. The method of claim 35, wherein said first cell is transfected with a composition of claim 14.
- 37. The method of claim 35, wherein said first cell is transfected with a gene of claim 16.
- 38. The method of claim 33, wherein said AJ172—2 protein is a protein of claim 15.
- 39. The method of claim 33, wherein said first cell and said second cell are cells of the same type.
- 40. The method of claim 33, wherein at least one of said first cell and said second cell are transfected to express an additional protein other than said AJ172—2 protein.
- 41. A method of inhibiting cell-cell fusion between a first cell which expresses an AJ172—2 protein and a second cell, said method comprising contacting said first cell with an AJ172—2 protein antagonist.
- 42. The method of claim 41, wherein said antagonist is selected from the group consisting of an antibody or antibody fragment directed to an AJ172—2 protein, an antisense polynucleotide directed to a polynucleotide expressing an AJ172—2 protein, a nucleotide aptamer directed to an AJ172—2 protein, a peptide aptamer directed to an AJ172—2 protein and a small molecule which blocks the fusion-inducing activity of an AJ172—2 protein.
- 43. The method of claim 41, wherein said first cell is a placental cell.
- 44. The method of claim 43, wherein said second cell is a cell from the maternal uterine lining.
- 45. The method of claim 41, wherein said first cell is a cytotrophoblast.
- 46. A method of inhibiting blastocyst implantation, said method comprising contacting a cell within said blastocyst which expresses an AJ172—2 protein with an AJ172—2 protein antagonist.
- 47. A method of inhibiting trophoblast invasion, said method comprising contacting a first cell which expresses an AJ172—2 protein with an AJ172—2 protein antagonist.
- 48. The method of claim 42, wherein said antagonist is selected from the group consisting of an antibody or antibody fragment directed to an AJ172—2 protein, an antisense polynucleotide directed to a polynucleotide expressing an AJ172—2 protein, a nucleotide aptamer directed to an AJ172—2 protein, and a peptide aptamer directed to an AJ172—2 protein.
- 49. The method of claim 48, wherein said antagonist is selected from the group consisting of an antibody or antibody fragment directed to an AJ172—2 protein, and an antisense polynucleotide directed to a polynucleotide expressing an AJ 172—2 protein.
- 50. A method of diagnosing or predicting the existence of a condition associated with disregulation of AH172—2 protein in a mammalian subject, said method comprising (a) determining a first level of expression of AJ172—2 protein in said subject, and (b) comparing said first level of expression to a second level of expression of AJ172—2 protein in one or more other mammalian subjects which do not have said condition.
- 51. The method of claim 50, wherein said condition is selected from the group consisting of pre-eclampsia, placental pathology and cancer.
- 52. The method of claim 50, wherein said first level of expression is determined in the serum of said subject.
- 53. The method of claim 50, wherein said first level of expression is determined using an antibody or antibody fragment directed to AJ172—2 protein.
- 54. The method of claim 51, wherein said cancer is choriocarcinoma.
- 55. A method of treating a neoplastic disease in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of an agent which modulates the expression or function of AJ172—2.
- 56. The method of claim 55, wherein said disease is choriocarcinoma.
- 57. A method of inhibiting metastasis in a mammalina subject, said method comprising administering to said subject a therapeutically effective amount of an agent which modulates the expression or function of AJ172—2.
Parent Case Info
[0001] This application is a continuation-in-part of application Ser. No. 09/080,478, filed May 18, 1998, which was a continuation-in-part of application Ser. No. 08/976,110, filed Nov. 21, 1997, which was a continuation-in-part of the following applications: Ser. No. 08/686,878, filed Jul. 26, 1996; Ser. No. 08/702,081, filed Aug. 23, 1996, which is a continuation-in-part of Ser. No. 08/686,878; Ser. No. 08/721,489, filed Sep. 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878; and 08/721,924, filed Sep. 27, 1996, which is a continuation-in-part of Ser. No. 08/686,878. All of such applications are incorporated by reference herein.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09175928 |
Oct 1998 |
US |
Child |
10016249 |
Oct 2001 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
09080478 |
May 1998 |
US |
Child |
09175928 |
Oct 1998 |
US |
Parent |
08976110 |
Nov 1997 |
US |
Child |
09080478 |
May 1998 |
US |
Parent |
08686878 |
Jul 1996 |
US |
Child |
08976110 |
Nov 1997 |
US |
Parent |
08721489 |
Sep 1996 |
US |
Child |
09175928 |
|
US |
Parent |
08721924 |
Sep 1996 |
US |
Child |
09175928 |
|
US |